Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have received an average rating of “Hold” from the five analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $14.50.

Several equities research analysts recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. HC Wainwright reissued a “buy” rating on shares of Agenus in a research report on Monday, October 20th.

Agenus Stock Performance

Agenus stock opened at $3.91 on Friday. The firm has a market cap of $132.97 million, a price-to-earnings ratio of -1.84 and a beta of 1.58. Agenus has a 1 year low of $1.38 and a 1 year high of $7.34. The firm’s 50 day moving average price is $3.87 and its two-hundred day moving average price is $4.45.

Agenus (NASDAQ:AGEN) last issued its earnings results on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The company had revenue of $30.24 million during the quarter, compared to analyst estimates of $80.39 million. As a group, equities analysts predict that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Trading of Agenus

A number of institutional investors have recently added to or reduced their stakes in AGEN. Vanguard Group Inc. boosted its stake in Agenus by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock valued at $9,893,000 after purchasing an additional 36,983 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Agenus by 3,080.3% during the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after buying an additional 427,604 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Agenus in the second quarter valued at approximately $1,976,000. Bank of America Corp DE boosted its position in shares of Agenus by 110.0% in the second quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after acquiring an additional 220,327 shares during the period. Finally, Walleye Capital LLC acquired a new stake in shares of Agenus in the second quarter worth $906,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.